AbbVie Inc. 8-K

What Happened AbbVie Inc. announced on June 22, 2026 that it has entered into a definitive agreement to acquire Apogee Therapeutics, Inc. The companies issued a joint press release and AbbVie provided an investor presentation describing the proposed transaction. The disclosure was made under Item 7.01 (Regulation FD disclosure) of Form 8-K and filed the same day.

AbbVie representatives presented information about the proposed transaction to investors on June 22, 2026. The Form 8-K attaches the joint press release and the investor slide deck as exhibits.

Key Details

• Filing date: June 22, 2026 (Form 8-K).
• Parties: AbbVie Inc. (buyer) and Apogee Therapeutics, Inc. (target).
• Exhibits attached: Exhibit 99.1 — joint press release; Exhibit 99.2 — investor presentation slides; Exhibit 104 — Inline XBRL cover page.
• Disclosure type: Item 7.01 Regulation FD disclosure; investor presentation was delivered to investors on June 22, 2026.

Why It Matters This 8-K signals a material corporate development: AbbVie is acquiring Apogee, which may affect AbbVie’s product pipeline, strategy, and future results depending on the transaction terms and integration. The Form 8-K itself attaches the press release and investor slides but does not include detailed transaction economics in the filing text; investors should review the attached exhibits for further details and wait for subsequent filings (e.g., additional 8-Ks or an 10-Q/8-K with financial terms) for purchase price, closing conditions and timing.